The new acting FDA head defies expectations, 1.17 billion people with mental disorders, and more health news from Morning Rounds
Vetenskapsnyheter
Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.
WASHINGTON — People in the food world didn’t know what to expect when the Trump administration appointed a little-known Florida attorney as the FDA’s top food official in 2025. They…
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
A State Department plan scheduled to be implemented June 1 would strip the U.S. of decades of disease defense, write eight former CDC directors.
“Women and girls in eastern Congo will be harmed in predictable, named ways over the next 12 months,” write researchers Lindsay Stark and Ilana Seff.
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
“There's a whole industry that seems to have sprung up”: Two experts on the people profiting from the rise of the perimenopause movement.
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable showdown with provider groups.
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
Seed oil panic, how STIs spread, and more health news from Morning Rounds
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.
Supporters worry that a men’s health office created by the Trump administration risks being dismantled by a future Democratic president
“My patients are replacing olive oil with beef tallow, even if they don't tell me during cardiac rehab,” writes a clinical dietitian.
This skeptic of AI in medicine sees one place where it could be valuable.
How a pharma company is soliciting research that can be used to blunt pharma proposed reforms in Washington.
The company behind the analytics, Vizient, touts MGH's increasing hospice enrollment to improved mortality performance.
Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.
Besides showing skepticism on the budget, senators grilled the NIH director about a leadership vacuum, two viral outbreaks, and the pace of funding.
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the…
RFK Jr. is urging limits on how much screen time kids get, in a new government advisory.
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout